Glenmark Life Sciences Q3 Results: Profit rises 1% on API strength
Glenmark Life Sciences, which was spun off from Glenmark Pharmaceuticals in 2019 to focus on the API business, posted revenue from operations of 5.41 billion rupees, up 3.5% from the previous year.